News Zepatier to add competition to Europe’s hep C market Will company pursue same aggressive pricing strategy in Europe?
Views & Analysis Many millions still untreated – but hep C boom is already ov... Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
News German pricing changes to hit blockbuster revenues But pharma will be able to negotiate confidential prices.
News NHS under fire for rationing hep C drugs NHS England tried to interfere with NICE appraisals, says BMJ.
News Halozyme abandons its €2bn pursuit of Evotec Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
